VERAVera Therapeutics, Inc.

Nasdaq veratx.com


$ 38.46 $ -0.55 (-1.41 %)    

Tuesday, 11-Jun-2024 15:59:55 EDT
QQQ $ 468.10 $ 3.19 (0.69 %)
DIA $ 388.08 $ -1.32 (-0.34 %)
SPY $ 537.01 $ 1.29 (0.24 %)
TLT $ 91.83 $ 0.94 (1.03 %)
GLD $ 214.15 $ 0.61 (0.29 %)
$ 38.43
$ 38.91
$ 0.00 x 0
$ 38.49 x 200
$ 37.69 - $ 39.15
$ 8.48 - $ 50.78
588,436
na
1.96B
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-28-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-25-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 06-24-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wall-street-snaps-five-week-winning-streak-economic-growth-slows-inflation-holds-steady-in-april-this-week-in-the-market

U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home pri...

 jp-morgan-maintains-overweight-on-vera-therapeutics-raises-price-target-to-65

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $...

 nvidia-is-up-186-from-a-year-ago-yet-these-7-stocks-have-more-than-doubled-their-returns-over-the-ai-chipmaker

NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance r...

 reported-saturday-vera-therapeutics-presented-72-week-egfr-stabilization-and-rapid-hematuria-improvement-in-phase-2b-origin-study-of-atacicept-in-igan-at-the-61st-european-renal-association-congress

72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improveme...

 raymond-james-maintains-strong-buy-on-vera-therapeutics-raises-price-target-to-68

Raymond James analyst Steven Seedhouse maintains Vera Therapeutics (NASDAQ:VERA) with a Strong Buy and raises the price targ...

 update--vera-therapeutics-q1-eps-056-up-from-080-yoy

Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.56) per share. This is a 30 percent increase over losses of $(...

 vertexs-alpine-acquisition-unpacking-analyst-predictions-on-povetacicepts-potential-impact

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-media...

 why-rallybio-shares-are-trading-higher-by-around-78-here-are-20-stocks-moving-premarket

Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collabo...

 guggenheim-reiterates-buy-on-vera-therapeutics-maintains-56-price-target

Guggenheim analyst Vamil Divan reiterates Vera Therapeutics (NASDAQ:VERA) with a Buy and maintains $56 price target.

 guggenheim-maintains-buy-on-vera-therapeutics-raises-price-target-to-56

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $27 to ...

 wedbush-maintains-neutral-on-vera-therapeutics-raises-price-target-to-34

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and raises the price target from $21 to...

 10m-bet-on-arrivent-biopharma-check-out-these-4-stocks-insiders-are-buying

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

 vera-therapeutics-prices-upsized-public-offering-of-8064517-class-a-common-stock-at-31share

The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and estimated offering ex...